CLIC-1901 (Ottawa Hospital Research Institute)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCLIC-1901 (Ottawa Hospital Research Institute)

Drug Alias NameCLIC-1901

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesThe Ottawa Hospital Research Institute

China Registration ClassN/A

Develop Information

Active CompaniesThe Ottawa Hospital Research Institute

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A